 Mesoblast Limited NASDAQ: MESO has announced the presentation of 90-day survival outcomes from the remestemcel-L trial in ventilator-dependent COVID-19 patients with moderatesevere acute respiratory distress syndrome ARDS. The data were presented at the International Society for Cell Gene Therapy Scientific Signatures Series on Cell and Gene Therapies in Lung Diseases and Critical Illnesses. 